ライフサイエンスコーパス: vitamin B6

1 5'-phosphate (PLP), the major active form of vitamin B6 .

2 in the catabolism of pyridoxal 5'-phosphate (Vitamin B6).

3 hesis of thiamin (vitamin B1) and pyridoxal (vitamin B6).

4 of pyridoxal-5-phosphate, an active form of vitamin B6.

5 e rehydration, prostaglandin inhibitors, and vitamin B6.

6 luences, including low intakes of folate and vitamin B6.

7 se with higher dietary intakes of folate and vitamin B6.

8 e those of red cell folate, vitamin B12, and vitamin B6.

9 cysteine are related to levels of folate and vitamin B6.

10 bolism requires several nutrients, including vitamin B6.

11 ated dementia (HAD) as well as deficiency of vitamin B6.

12 tine (200 mg), niacin (16 mg), zinc (10 mg), vitamin B6 (1.4 mg), vitamin B2 (1.4 mg), folic acid (40

13 dose B-vitamin treatment (folic acid 0.8 mg, vitamin B6 20 mg, vitamin B12 0.5 mg) slowed shrinkage o

14 Pyridoxal 5'-phosphate (PLP, vitamin B6), a cofactor in many enzymatic reactions, has

15 se results suggest that intake of folate and vitamin B6 above the current recommended dietary allowan

16 plasma vitamin B12, homocysteine, folate and vitamin B6 (active form pyridoxal 5'-phosphate, PLP), we

17 er, upon prompt treatment with high doses of vitamin B6, affected patients can have a normal developm

18 increased K(m) for succinyl-CoA, and reduced vitamin B6 affinity.

19 talyzes the production of the active form of vitamin B6 (also known as pyridoxal 5'-phosphate [PLP]),

20 PdxK), an enzyme required for the salvage of vitamin B6, an essential enzymatic cofactor.

21 5'-phosphate (PLP) is the active vitamer of vitamin B6 and acts as an essential cofactor in many asp

22 In contrast, the relationship between vitamin B6 and atherosclerosis was independent of homocy

23 ed in early pregnancy, and concentrations of vitamin B6 and B12 declined throughout pregnancy, becomi

24 In contrast, use of vitamin B6 and B12 from individual supplement sources, b

25 For vitamin B6 and B12, the risk was even higher among men w

26 and controls found reduced concentrations of vitamin B6 and branched-chain amino acids in PSC (P < .0

27 e treatment consists of symptom control with vitamin B6 and doxylamine, hydration, and adequate nutri

28 temperatures a decrement of lactoperoxidase, vitamin B6 and folic acid was observed.

29 48, p = 8.30 x 10(-18)) were associated with vitamin B6 and FUT2 (rs602662, [corrected] p = 2.83 x 10

30 ate (PLP) is the biologically active form of vitamin B6 and is an important cofactor for several of t

31 gest that one-carbon nutrients, particularly vitamin B6 and methionine, may be protective against NHL

32 l-1 metabolites, including those involved in vitamin B6 and tyrosine metabolism.

33 g of its metabolism and of the importance of vitamins B6 and B12 and folate as well as enzyme levels

34 B vitamins, including folic acid and vitamins B6 and B12 are the mainstay of treatment of pat

35 Vitamins B6 and B12 belong to the same group of hydrophi

36 by daily supplementation with folic acid and vitamins B6 and B12 did not reduce the risk of developin

37 hed in methionine but depleted in folate and vitamins B6 and B12 increased atherosclerotic lesion are

38 Intakes of choline, folate, methionine, and vitamins B6 and B12 were assessed using a food frequency

39 Homocysteine, folate, and vitamins B6 and B12 were measured in preconception plasm

40 tHcy plasma levels are influenced by folate, vitamins B6 and B12, as well as by hereditary factors.

41 urrent (>=2) intakes of one-carbon cofactors vitamins B6 and B12, choline, betaine, and methionine an

42 aining the recommended dietary allowances of vitamins B6 and B12, in a randomized, double-blind, plac

43 cysteine and concomitantly reduced levels of vitamins B6 and B12, in plasma of AVNFH patients.

44 This work reviews the significant aspects of vitamins B6 and B12: their vital roles, consequences of

45 amine the association between the intakes of vitamins B6 and C and risk of kidney stone formation in

46 The relation between the intake of vitamins B6 and C and the risk of symptomatic kidney sto

47 homocysteine-lowering trials with folate and vitamins B6 and/or B12 tested as protective agents again

48 ic acid, 100 mg of pyridoxine hydrochloride (vitamin B6), and 2 mg of cyanocobalamin (vitamin B12) or

49 TR received 2.4 mg/day of FA, 50.0 mg/day of vitamin B6, and 0.4 mg/day of vitamin B12, while the HD

50 ation pill of 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12.

51 combination pill of 2.5 mg folic acid, 50 mg vitamin B6, and 1 mg vitamin B12) or to the placebo grou

52 upplementation (2.5 mg/d folic acid, 50 mg/d vitamin B6, and 1 mg/d vitamin B12), respectively.

53 rahydrofolate, in addition to 50.0 mg/day of vitamin B6, and 1.0 mg/day of vitamin B12.

54 , 0.65-0.90), the major source of folate and vitamin B6, and after excluding multiple vitamin users,

55 elated to the B vitamins folate, riboflavin, vitamin B6, and cobalamin were measured at diagnosis and

56 were concentrations of folate, vitamin B12, vitamin B6, and creatinine.

57 ciency include aging, deficiency of iron and vitamin B6, and exposure to toxic metals such as aluminu

58 e model to study the effects of vitamin B12, vitamin B6, and folate deficiencies and explain why homo

59 Vitamin B6, and vitamers thereof, have been associated w

60 d risks of antioxidant vitamins, folic acid, vitamin B6, and vitamin B12 among women with CVD or > or

61 follow-up, a combination pill of folic acid, vitamin B6, and vitamin B12 did not reduce a combined en

62 ve a combination pill containing folic acid, vitamin B6, and vitamin B12 or a matching placebo, and w

63 (n=2056) or low dose (n=2054) of folic acid, vitamin B6, and vitamin B12 to determine whether decreas

64 Serum concentrations of folate, vitamin B6, and vitamin B12 were assayed at examination

65 intakes and serum concentrations of folate, vitamin B6, and vitamin B12 were inversely associated wi

66 tively updated intake of B vitamins (folate, vitamin B6, and vitamin B12) as ascertained by repeated

67 tions by baseline intakes of dietary folate, vitamin B6, and vitamin B12.

68 Intakes and serum levels of folate, vitamin B6, and vitamin B12.

69 or the role of the vitamin cofactors folate, vitamin B6, and vitamin B12; and 3) adjustment for the p

70 nce level included calcium, folate, thiamin, vitamin B6, and vitamin C, with nutrient supply changes

71 id + anthranilic acid); an inverse marker of vitamin B6] and both reduced global quality of life (B =

72 s at low risk of bias indicated that ginger, vitamin B6, antihistamines, metoclopramide (for mild sym

73 homocysteine and deficiencies of folate and vitamin B6 are common in transplant recipients.

74 in part dependent upon enzymes that require vitamin B6 as a cofactor, we tested the hypothesis that

75 Here, we identify pyridoxal (vitamin B6) as a naturally presented MR1 ligand using un

76 e pyridoxal 5'-phosphate, the active form of vitamin B6, as a cofactor for their activity.

77 that produces pyridoxal phosphate (PLP) from vitamin B6-as an acute myeloid leukemia (AML)-selective

78 an alternative therapeutic entry point into vitamin B6-associated pathologies.

79 ted nominally with decreased risk-vitamin A, vitamin B6, B-carotene, lutein and zeaxanthin, magnesium

80 with lower daily protein, dietary fiber, and vitamin B6, B12, and C intake (p < 0.05).

81 d in the intervention group were riboflavin, vitamins B6, B12, and D (in amounts available in over-th

82 of homocysteine and lower concentrations of vitamins B6, B12, and folate increase the risk for cogni

83 We examined the relation between vitamins B6, B12, and folate intake on cortical volume u

84 rthermore, there was no relationship between vitamins B6, B12, or folate intake on global brain volum

85 upon dietary supplementation with folate and vitamins B6/B12.

86 lic drug interconversion involving bacterial vitamin B6, B9, and ribonucleotide metabolism.

87 ver, intakes of fruit and vegetables, fiber, vitamins B6, B9, C, D, and E, iron, and magnesium were h

88 rcentile (<513 nmol/L) and concentrations of vitamin B6 below the lowest 20th percentile (<23.3 nmol/

89 ted nominally with decreased risk-vitamin A, vitamin B6, beta-carotene, lutein and zeaxanthin, magnes

90 This study thus expands our knowledge of vitamin B6 biology and highlights the importance of PLP

91 fundamental differences in the regulation of vitamin B6 biosynthesis across the two lineages.

92 me (PDX1.2), which is involved in regulating vitamin B6 biosynthesis de novo under stress conditions.

93 pseudoenzyme acts as a positive regulator of vitamin B6 biosynthesis during such stress conditions in

94 catalytic homolog of the PDX1 subunit of the vitamin B6 biosynthesis protein machinery, PYRIDOXINE BI

95 Two functional pathways, L-ornithine and vitamin B6 biosynthesis, were associated with better soc

96 s rescued by elevated levels of the cofactor vitamin B6, but also alleles rescued by elevated heme, a

97 0.77 SDS (95% CI 0.68 to 0.87, p < 0.0001), vitamin B6 by 1.07 SDS (0.99 to 1.14, p < 0.0001), vitam

98 d how well the foetus has been supplied with vitamin B6 by the mother.

99 nutrition as partially available sources of vitamin B6, (c) undergo partial hydrolysis by a novel ma

100 c acid/(pyridoxal + PLP), reflects increased vitamin B6 catabolism during inflammation.

101 tudy provides robust evidence that increased vitamin B6 catabolism is independently associated with a

102 xal kinase (PDXK), a key metabolic enzyme of vitamin B6 catalyzing phosphorylation of pyridoxal (PL),

103 We hypothesized that pyridoxal phosphate (vitamin B6 coenzyme) was de-activated by L-Delta(1)-pyrr

104 The vitamin B6 cofactor pyridoxal was conjugated with the lu

105 sent work reports the interaction of various vitamin B6 cofactors with the red emitting glutathione s

106 Vitamin B6 comprises a family of compounds that is essen

107 of participants developed low late-pregnancy vitamin B6 concentrations (pyridoxal 5-phosphate <20 nmo

108 Folate and vitamin B6 concentrations were lower (5.9+/-4.2 vs. 7.9+

109 oliferation under both physiological and low vitamin B6 conditions.

110 Lower levels of folate and vitamin B6 confer an increased risk of atherosclerosis.

111 The results show that the level of the vitamin B6 conjugate in the circulation of control subje

112 2 knockdown lines demonstrates that boosting vitamin B6 content is dependent on PDX1.2, revealing tha

113 ell as natural compounds such as pyridoxine (vitamin B6), cyanocobalamin (vitamin B12), and apigenin

114 ts showed little change in expression of the vitamin B6 de novo pathway genes, but significant increa

115 Vitamin B6 de-activation may contribute to seizures in h

116 Folate and vitamin B6 deficiencies were seen in 10.8% and 17.91% of

117 Vitamin B6 deficiency has been linked to cognitive impai

118 We previously identified vitamin B6 deficiency in a child presenting with seizure

119 normalized to age established a cut-off for vitamin B6 deficiency in both cohorts, identifying 17 of

120 preconception, and many developed markers of vitamin B6 deficiency in late pregnancy.

121 Emerging evidence suggests that vitamin B6 deficiency or its metabolic dysregulation per

122 Vitamin B6 deficiency was more frequent in patients than

123 fy the most important factors that predicted vitamin B6 deficiency while using the resulting tree to

124 ing GAD dysfunction such as schizophrenia or vitamin B6 deficiency.

125 o=0.7, 95% CI: 0.4, 1.1) than did women with vitamin B6 deficiency.

126 ight to optimal cats appear to be at risk of vitamin B6 deficiency.

127 th cohorts, identifying 17 of 101 animals as vitamin B6 deficient.

128 X1.1 expression, accounting for the stronger vitamin B6 deficit in pdx1.3 compared with pdx1.1.

129 recently been shown to cause a novel form of vitamin B6-dependent epilepsy, the pathophysiological ba

130 Moreover, vitamin B6-dependent processes can modulate several tumo

131 series of novel polyglycosylated fluorinated vitamin B6 derivatives as 19F NMR-sensitive aglycons for

132 Results Use of supplemental vitamins B6, folate, and B12 was not associated with lun

133 Plants are the major source of vitamin B6 for animals, yet the biosynthesis pathway and

134 This study examined the release of vitamin B6 from a hydrogel made of whey protein isolate

135 doxal 5'-phosphate (PLP), the active form of vitamin B6, functions as a cofactor in humans for more t

136 risk among men in the highest categories of vitamin B6 (> 20 mg/d; hazard ratio, 1.82; 95% CI, 1.25

137 Women with sufficient vitamin B6 had a higher adjusted hazard ratio of concept

138 with a lower risk of NHL, but that for only vitamin B6 (highest vs. lowest quartile: odds ratio = 0.

139 alyses demonstrate an important link between vitamin B6 homeostasis and nitrogen metabolism.

140 bution of these various pathways to cellular vitamin B6 homeostasis in plants is not fully understood

141 ss conditions, which would serve to maintain vitamin B6 homeostasis in times of need in eudicots that

142 0.23; 95% CI, 0.17-0.33; P for trend < .001; vitamin B6: HR, 0.48; 95% CI, 0.34-0.67; P for trend < .

143 for the detection of two major components of vitamin B6 i.e. pyridoxine (Py) and pyridoxal-5'-phospha

144 an evolutionarily conserved requirement for vitamin B6 in enabling the Ca(2+) response to glucose in

145 e successfully exploited for the analysis of vitamin B6 in food supplements.

146 tary measures to further explore the role of vitamin B6 in health.

147 rological disorders as well as deficiency of vitamin B6 in human being.

148 rological disorders as well as deficiency of vitamin B6 in human being.

149 mbranes, implying a potential involvement of vitamin B6 in membrane function.

150 Our study establishes a critical role of vitamin B6 in plant development and stress tolerance and

151 the biosynthesis pathway and the function of vitamin B6 in plants are not well elucidated.

152 idoxine 5'-beta-D-glucoside, a major form of vitamin B6 in plants, we detected two cytosolic beta-glu

153 Vitamin B6 in the form of pyridoxine (PN) is one of the

154 These species increase the levels of vitamin B6 in the gut lumen.

155 insights into the multifaceted functions of vitamin B6 in tumorigenesis.

156 Major differences in the metabolism of vitamin B6 in various cancers compared to their normal c

157 ission, including depletion of serotonin and vitamin B6, in the AIMD mice.

158 Other forms of vitamin B6 include pyridoxamine 5'-phosphate (PMP), pyri

159 Vitamin B6 insufficiency has been linked to increased ri

160 ssociations of the 5 biomarker outcomes with vitamin B6 intake and personal and lifestyle covariates.

161 processes, varied in their associations with vitamin B6 intake and personal and lifestyle predictors.

162 Kr), and the 4-pyridoxic acid ratio (PAr) to vitamin B6 intake as well as personal and lifestyle char

163 s to resolution, while neither celecoxib nor vitamin B6 intake attenuated OIPN.

164 n in the highest quintile of both folate and vitamin B6 intake compared with the opposite extreme.

165 analysis, we found that adults with greater vitamin B6 intake had greater gray matter volume along t

166 s were observed between multivitamin use and vitamin B6 intake on myocardial infarction, between mult

167 Vitamin B6 intake was most strongly associated with PLP,

168 treatment duration, but not celecoxib use or vitamin B6 intake, may be associated with significantly

169 r (fold change in marker given a doubling of vitamin B6 intake: PLP 1.60 [95% credible interval (CrI)

170 Vitamin B6 is a metabolic cofactor that underpins critic

171 A diet poor in folic acid and vitamin B6 is also associated with a higher risk of deve

172 Vitamin B6 is an enzymatic co-factor that is vital for c

173 Vitamin B6 is an indispensable compound for survival, we

174 the phosphorylated and the oxidized form of vitamin B6 is an organic cofactor.

175 Vitamin B6 is indispensible for all organisms, notably a

176 Vitamin B6 is involved in a variety of enzymatic transfo

177 Pyridoxine (vitamin B6) is a cofactor required by numerous enzymes i

178 some essential nutrients (Inulin, DHA & EPA, vitamins B6, K1, and D3) as enhancers of calcium bioavai

179 tablishes an association between an index of vitamin B6 levels with lung cancer risk.

180 entrations may be caused by lower folate and vitamin B6 levels.

181 ate, B12, and pyridoxal 5'-phosphate (active vitamin B6) levels, along with other potential determina

182 High doses of vitamin B6 may decrease oxalate production, whereas vita

183 Large doses of vitamin B6 may reduce the risk of kidney stone formation

184 pment and stress tolerance and suggests that vitamin B6 may represent a new class of antioxidant in p

185 e (PLP), the co-enzymatically active form of vitamin B6, may represent an alternative therapeutic ent

186 A38-null K562 cells in physiological and low vitamin B6 media can be explained by the loss of serine

187 8 microg/d) and 0.67 (95% CI, 0.53-0.85) for vitamin B6 (median intake, 4.6 mg/d vs 1.1 mg/d).

188 herapeutic hypothermia through regulation of vitamin B6 metabolism and PDXK serves as a previously un

189 Furthermore, it proposes dynamic vitamin B6 metabolism as a promising therapeutic axis, o

190 significant rises in glycerophospholipid and vitamin B6 metabolism related to HSC expansion and diffe

191 he tumor-specific spatiotemporal dynamics of vitamin B6 metabolism uncover context-dependent metaboli

192 rices, with some plant-animal overlap (e.g., Vitamin B6 metabolism).

193 ins that have been implicated in pyridoxine (vitamin B6) metabolism in the filamentous fungi Cercospo

194 Vitamin B6 metabolites were borderline low in all family

195 Vitamin B6 needs further study to clarify its role in re

196 Studies addressing the role of vitamin B6 nutrition in regulating the activity and its

197 point more strongly to the possibility that vitamin B6 offers independent protection.

198 f dietary folate (OR, 0.7; 95% CI, 0.4-1.3), vitamin B6 (OR, 0.5; 95% CI, 0.3-1.0), vitamin B12 (OR,

199 livery vehicle for the controlled release of vitamin B6 over a prolonged period of observation.

200 trend < .001), 0.61 (95% CI, 0.46-0.81) for vitamin B6 (P for trend = .002), and 0.74 (95% CI, 0.58-

201 Our work identifies the vitamin B6 pathway as a pharmacologically actionable dep

202 eration, and pharmacological blockade of the vitamin B6 pathway at both PDXK and PLP levels recapitul

203 idoxal 5'-phosphate (PLP, the active form of vitamin B6) perform a myriad of diverse chemical transfo

204 l/1.73m(2)/24hours for PH1 not responsive to vitamin B6, PH2, and PH3, respectively) but was signific

205 . demonstrate that pyridoxal kinase promotes vitamin B6 phosphorylation, producing the active form py

206 tin can be improved by combining it with the vitamin B6 precursor pyridoxine.

207 for 2-3 weeks with high doses of pyridoxine (vitamin B6) produced a profound proprioceptive loss, sim

208 a impacts microbiota composition, decreasing vitamin B6 production and promoting sustained colonizati

209 ose-stimulated Ca(2+) response, we highlight vitamin B6 production as a signature pathway of first re

210 n stress, concomitant with an enhancement of vitamin B6 production.

211 erties of the enzyme complex responsible for vitamin B6 (pyridoxal 5-phosphate, PLP) biosynthesis in

212 oamines and their cofactors (the pterins and vitamin B6 (pyridoxal phosphate (PLP))) in human cerebro

213 Vitamin B6 (pyridoxal phosphate) is an essential cofacto

214 and the observation that the active form of vitamin B6 (pyridoxal phosphate, P5P) modulates the self

215 the function of both PLPHP homologs perturbs vitamin B6 (pyridoxine) content, inducing a PLP deficit

216 ential enzymes and the intake of folic acid, vitamin B6 (pyridoxine), and vitamin B12 (cobalamin).

217 s, which are involved in the biosynthesis of vitamins B6 (pyridoxine) and B1 (thiamin).

218 001), vitamin B12 (r = -0.21; P = .001), and vitamin B6 (r = -0.18; P = .001).

219 rent markers, capturing different aspects of vitamin B6-related biological processes, varied in their

220 surable effect of network characteristics on vitamin B6 release.

221 linked to tumor growth, but the relevance of vitamin B6 remains uncertain.

222 upplements, including vitamin D, folate, and vitamin B6, remains uncertain, calcium supplementation i

223 tively) but was significantly higher than in vitamin B6 responsive patients with PH1.

224 In contrast, vitamin B6-responsive XLSA mutations p.Arg452Cys and p.A

225 al metabolic pathways of lipopolysaccharide, vitamin B6, riboflavin, pyruvate, and propionate functio

226 es, the epimerase homolog being fused to the vitamin B6 salvage enzyme pyridoxine 5'-phosphate oxidas

227 pimerase (NNRE), the latter being fused to a vitamin B6 salvage enzyme.

228 first report of a pyridoxal reductase in the vitamin B6 salvage pathway in plants.

229 Poor vitamin B6 status appears to decrease the probability of

230 ing biomarker concentrations indicating high vitamin B6 status are associated with a reduced risk of

231 llow-up of 3.2 y for OS, higher preoperative vitamin B6 status as assessed by PLP and the functional

232 operative blood samples were used to measure vitamin B6 status by the direct marker pyridoxal 5'-phos

233 Limited studies are available on vitamin B6 status in domestic cats.

234 nvestigated survival outcomes in relation to vitamin B6 status in prospectively followed CRC patients

235 Higher preoperative vitamin B6 status is associated with improved OS among s

236 Vitamin B6 status is best assessed by using a combinatio

237 Higher vitamin B6 status was associated with better quality of

238 ards regression, we examined associations of vitamin B6 status with overall survival (OS), disease-fr

239 hosphate (PLP) is a commonly used measure of vitamin B6 status.

240 logies remain poorly understood, and whether vitamin B6 supplementation improves cognition is unclear

241 Thus, our study supports that vitamin B6 supplementation may be indicated in junior to

242 Vitamin B6 supplementation resolves epilepsy in patients

243 , but they may be preventable with long term vitamin B6 supplementation.

244 erences in the abundance of genes related to vitamin B6 synthesis and branched-chain amino acid synth

245 e show that SOR1 is essential in pyridoxine (vitamin B6) synthesis in C. nicotianae and Aspergillus f

246 ot synthesise themselves, such as pyridoxine/vitamin B6, taurine, some essential amino acids, and a c

247 ngle fixed-dose pill, along with pyridoxine (vitamin B6), that would be taken once per day to help wi

248 on or supplementation of dietary pyridoxine (vitamin B6), the essential cofactor of ALAS2, on the ane

249 for remethylation; low intake (<2.1 mg/d) of vitamin B6, the cofactor in the catabolic pathway of hom

250 Relative to women in the lowest quartile of vitamin B6, those in the third and fourth quartiles had

251 Transport patterns of vitamin B6 through the polymeric matrix were monitored o

252 cofactor pyridoxal-5'-phosphate (PLP, active vitamin B6) through its complexation with P6C.

253 Still, the molecular mechanisms linking vitamin B6 to these pathologies remain poorly understood

254 subset of patients manages the disease with vitamin B6 treatments, the only effective treatment for

255 late was significantly different only to the vitamin B6-unresponsive PH1 group.

256 a rate-limiting enzyme in converting dietary vitamin B6 (VB6) to pyridoxal 5'-phosphate (PLP), the bi

257 e pathway that interconverts between the six vitamin B6 vitamers.

258 Other nutritional supplements, such as vitamin B6, vitamin A, multivitamins, antioxidants, and

259 se findings highlight mechanisms that affect vitamin B6, vitamin B12 and homocysteine serum levels.

260 l micronutrient insufficiency in riboflavin, vitamin B6, vitamin B12, and vitamin D, before and durin

261 gate genetic factors that affect circulating vitamin B6, vitamin B12, folate and homocysteine, a geno

262 s and measured serum concentrations of iron, vitamin B6, vitamin B12, zinc, folate, ferritin, total i

263 with decreased risk of late AMD: vitamin A, vitamin B6, vitamin C, folate, B-carotene, lutein and ze

264 with decreased risk of late AMD: vitamin A, vitamin B6, vitamin C, folate, beta-carotene, lutein and

265 A high intake of vitamin B6 was inversely associated with risk of stone f

266 d from the formulation in 1976), pyridoxine (vitamin B6)), was associated with a lower risk for conge

267 Here, using the example of vitamin B6, we investigate the regulation of biosynthesi

268 f pyridoxal 5'-phosphate (the active form of Vitamin B6), which we validate experimentally via multic

269 concentrations and low levels of folate and vitamin B6, which could contribute to the development of

270 LPL gene likely influences the catabolism of vitamin B6 while FUT2 interferes with absorption of vita

271 to examine plasma concentrations of folate, vitamin B6 [whose main circulating form is pyridoxal-5'-

272 ody mass index (BMI), diabetes mellitus, and vitamin B6 with oxaliplatin-induced peripheral neuropath

273 both plr1 mutants had lower levels of total vitamin B6, with significantly decreased levels of pyrid

274 higher for men than for women for magnesium, vitamin B6, zinc, vitamin C, vitamin A, thiamin, and nia